New Arthritis Drug Effective in Trials

Thursday, 13 Jun 2013 12:00 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Eli Lilly and Co and Incyte Corp said their experimental drug was effective in reducing painful symptoms associated with rheumatoid arthritis after 52 weeks of treatment.
 
The drug, baricitinib, is part of a new family of medicines called JAK inhibitors that block enzymes believed to be involved in the inflammatory process.
 
If approved, the pill will compete against injected rheumatoid arthritis drugs that currently dominate the market. Pfizer Inc's Xeljanz was the first such pill to hit the shelves last year.
 
Lilly and Incyte had released trial data on baricitinib last year after 12 and 24 weeks of treatment.
 
Lilly also started late-stage trials after the drug showed positive results after 24 weeks of treatment.
 
Patients who completed week 24 were eligible to receive either the 4 mg or 8 mg once daily dose through week 52.
 
Of the 196 patients in the study, 71 percent showed a 20 percent improvement in rheumatoid arthritis symptoms.
 
"In the long-term extension, the clinical improvements observed at week 24 were sustained through 52 weeks in (rheumatoid arthritis) patients," the companies said in a statement.
 
Rheumatoid arthritis is an autoimmune disorder that causes inflammation and damage to the joints and surrounding tissues.
 
Lilly shares closed at $51.78 on the New York Stock Exchange on Wednesday, while Incyte shares closed at $20.55 on the Nasdaq.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

ER Study: Too Many Kids Prescribed Codeine

Monday, 21 Apr 2014 08:28 AM

Despite recommended limits on codeine use in children, the potent painkiller is prescribed for children in at least half . . .

Yoga Eases PTSD Symptoms: Study

Monday, 21 Apr 2014 08:18 AM

Women enrolled in a small study reported a reduction in symptoms of post-traumatic stress disorder (PTSD) after a series . . .

Goodbye, Bulk: Today's Strength Training Is for Slimming Down

Monday, 21 Apr 2014 08:06 AM

Strength training, traditionally favored by body builders seeking to bulk up, has become the go-to regimen for athletes, . . .

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved